Cyclic Peptide Derivative Composition for Neovascularization and Edema
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ophthalmic diseases such as diabetic retinopathy and age-related macular degeneration are inadequate in effectively preventing or reversing choroidal and retinal neovascularization, retinal edema, and other related conditions that lead to significant vision loss.
Innovation Solution
Development of cyclic peptide derivative compositions that modulate nervous system cell activity, specifically targeting diabetic retinopathy and age-related macular degeneration, through compounds represented by specific structural formulas and their pharmaceutically acceptable salts, solvates, or prodrugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for ophthalmic diseases, then current standard therapies are applied, but they are inadequate in effectively preventing or reversing choroidal and retinal neovascularization and retinal edema
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of peptide compounds to create cyclic peptide derivatives with specific molecular configurations (Formula 1 and Formula 2 structures). These structural parameter changes enhance the compounds' ability to inhibit VEGF and other angiogenic factors, thereby effectively preventing and reversing choroidal and retinal neovascularization and retinal edema that conventional treatments fail to address
Solution Approach 2:
The patent employs composite materials by formulating cyclic peptide derivative compounds in combination with pharmaceutically acceptable carriers, excipients, and adjuvants to create composite pharmaceutical compositions. These composite formulations improve drug delivery, stability, and bioavailability, enabling effective treatment of ophthalmic diseases through optimized compound-delivery system integration
2Reliability
If new cyclic peptide derivative compositions are developed, then effectiveness against neovascularization and edema is improved, but treatment complexity and development requirements increase
Solution Approach 1:
The patent applies universality by designing cyclic peptide derivative compounds with broad-spectrum activity against multiple angiogenic factors including VEGF, bFGF, and PDGF. The compounds demonstrated in Formula 1 and Formula 2 structures can simultaneously target multiple pathways involved in neovascularization and edema formation, providing multi-functional treatment that addresses various aspects of ophthalmic diseases with a single agent, thereby improving effectiveness without proportionally increasing treatment complexity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides a cyclic peptide derivative composition for treating or preventing ophthalmic diseases. The present disclosure relates to a composition comprising a compound for treating or preventing ophthalmic diseases or a pharmaceutically acceptable salt, solvate or prodrug thereof. More specifically, the composition of the present disclosure can treat or prevent diabetic retinopathy, glaucoma or age-related macular degeneration. The technology provided by the present disclosure can be used for a cyclic peptide derivative for modulating nervous system cell activity and a method for producing said cyclic peptide derivative.